Meeting Coverage

ESMO Breast Cancer

European Society for Medical Oncology

Novel Combo Falters in Metastatic Triple-Negative Breast Cancer

No PFS benefit with addition of ceralasertib to olaparib

ESMO over a photo of Messe Berlin fairgrounds, Berlin Germany

Latest ESMO Breast Cancer Meeting Coverage

Antibody-Drug Conjugate Promising for Breast Cancer With Brain Mets

High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial

May 4, 2022